Joseph B Hiatt
Overview
Explore the profile of Joseph B Hiatt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
3419
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hiatt J, Doebley A, Arnold H, Adil M, Sandborg H, Persse T, et al.
Sci Adv
. 2024 Apr;
10(15):eadk2082.
PMID: 38598634
We report an approach for cancer phenotyping based on targeted sequencing of cell-free DNA (cfDNA) for small cell lung cancer (SCLC). In SCLC, differential activation of transcription factors (TFs), such...
2.
Doebley A, Ko M, Liao H, Cruikshank A, Santos K, Kikawa C, et al.
Nat Commun
. 2023 Jan;
14(1):403.
PMID: 36697405
No abstract available.
3.
Doebley A, Ko M, Liao H, Cruikshank A, Santos K, Kikawa C, et al.
Nat Commun
. 2022 Dec;
13(1):7475.
PMID: 36463275
Cell-free DNA (cfDNA) has the potential to inform tumor subtype classification and help guide clinical precision oncology. Here we develop Griffin, a framework for profiling nucleosome protection and accessibility from...
4.
Hiatt J, Sandborg H, Garrison S, Arnold H, Liao S, Norton J, et al.
Clin Cancer Res
. 2022 Aug;
28(20):4551-4564.
PMID: 35920742
Purpose: The addition of immune checkpoint blockade (ICB) to platinum/etoposide chemotherapy changed the standard of care for small cell lung cancer (SCLC) treatment. However, ICB addition only modestly improved clinical...
5.
Hiatt J, Romine P, Wu D
Semin Oncol
. 2022 Jul;
49(3-4):344-352.
PMID: 35843737
Small cell lung cancer (SCLC) is an aggressive neuroendocrine neoplasm with poor survival outcomes and little change to treatment standards over decades. SCLC is associated with heavy tobacco exposure and...
6.
Grunblatt E, Wu N, Zhang H, Liu X, Norton J, Ohol Y, et al.
Genes Dev
. 2020 Aug;
34(17-18):1210-1226.
PMID: 32820040
Small cell lung cancer (SCLC) is an aggressive neuroendocrine cancer characterized by initial chemosensitivity followed by emergence of chemoresistant disease. To study roles for amplification in SCLC progression and chemoresistance,...
7.
Augert A, Mathsyaraja H, Ibrahim A, Freie B, Geuenich M, Cheng P, et al.
Cancer Cell
. 2020 May;
38(1):97-114.e7.
PMID: 32470392
Small cell lung cancer (SCLC) is a highly aggressive and lethal neoplasm. To identify candidate tumor suppressors we applied CRISPR/Cas9 gene inactivation screens to a cellular model of early-stage SCLC....
8.
Hiatt J, MacPherson D
Cancer Discov
. 2019 May;
9(5):584-586.
PMID: 31043412
Small cell lung cancer (SCLC) has demonstrated modest responses to immune-checkpoint blockade despite harboring a high mutational burden. In this issue, Sen and colleagues show remarkable synergy between inhibition of...
9.
Appelbaum J, Wells D, Hiatt J, Steinbach G, Stewart F, Thomas H, et al.
J Immunother Cancer
. 2018 Sep;
6(1):82.
PMID: 30170630
Background: Immune checkpoint inhibitors (ICIs) are the treatment of choice for several cancers and can be associated with remarkable clinical benefit, but can also cause serious immune-related adverse events (irAEs)....
10.
Jansen L, Mirzaa G, Ishak G, ORoak B, Hiatt J, Roden W, et al.
Brain
. 2015 Feb;
138(Pt 6):1613-28.
PMID: 25722288
Malformations of cortical development containing dysplastic neuronal and glial elements, including hemimegalencephaly and focal cortical dysplasia, are common causes of intractable paediatric epilepsy. In this study we performed multiplex targeted...